단장증후군 시장 규모는 향후 몇 년 동안 연평균 14.6%의 성장률(CAGR)로 2029년까지 53억 3,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 장단장증후군(SBS) 유병률 증가, 비경구 및 경장영양 요법의 채택 확대, 임상 연구 및 의약품 개발 확대, 의료 지출 증가, SBS에 대한 인식 개선 및 조기 진단 등 여러 요인에 기인합니다. 예측 기간 동안 주요 동향으로는 장 재활 치료의 발전, 소장 이식 기술 개발, SBS 관리에서 원격의료의 채택, 경장영양 장치의 기술 혁신, SBS 치료 계획에 인공지능의 통합 등이 있습니다.
소화기 질환의 유병률 증가는 향후 몇 년 동안 단장증후군 시장의 성장을 촉진할 것으로 예상됩니다. 소화관 질환에는 위, 장, 간, 췌장 등 소화관에 영향을 미치는 다양한 질환이 포함되며, 소화 및 영양 흡수를 방해하는 경우가 많습니다. 이러한 질환의 증가는 장 건강을 해치고 염증을 촉진하는 건강에 해로운 식습관이 주요 원인으로 작용하고 있습니다. 위장 장애는 손상된 장의 일부를 외과적으로 절제해야 하고 장의 영양 흡수 능력을 저하시켜 단장증후군을 유발할 수 있습니다. 예를 들어, 2023년 9월, 염증성 장질환(IBD) 임상연구센터는 캐나다에서 32만 명 이상이 염증성 장질환(IBD)을 앓고 있으며, 매년 2.44%씩 증가하여 2035년까지 약 47만 명의 캐나다인이 IBD를 앓게 될 것으로 예상한다고 보고했습니다. 있을 것으로 예상됩니다. 결과적으로 소화기 질환의 유병률 증가가 단장증후군 시장의 성장을 견인하고 있습니다.
단장증후군 시장의 주요 업체들은 소화기 질환 환자의 예후를 개선하기 위해 장부전증에 대한 최첨단 치료법 개발에 주력하고 있습니다. 장 기능 부전은 소장이 충분한 영양소, 수분, 전해질을 흡수하지 못해 수분 공급과 영양 공급이 손상되는 심각한 상태입니다. 예를 들어, 2024년 5월 미국 헬스케어 기업 아이언우드 파마슈티컬스(Ironwood Pharmaceuticals)는 차세대 GLP-2 유사체인 아프라글루타이드(apraglutide)에 대한 단장증후군을 앓고 있는 성인을 대상으로 한 임상시험에서 얻은 새로운 데이터를 발표했습니다.의 장내 흡수를 촉진하고 비경구 보조제에 대한 의존도를 낮출 수 있는 가능성을 보여줌으로써 이 약물의 안전성, 유효성 및 장기적인 이점을 강조했습니다. 이번 성과는 소화기 질환에 대한 혁신적인 치료법 개발에 대한 아이언우드의 헌신을 강조하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 단장증후군 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업 분석
- 세계의 단장증후군 시장 : 성장률 분석
- 세계의 단장증후군 시장 실적 : 규모와 성장, 2019-2024
- 세계의 단장증후군 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 단장증후군 전체 시장(TAM)
제6장 시장 세분화
- 세계의 단장증후군 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 글루카곤 유사 펩티드(GLP-2)
- 성장호르몬
- 글루타민
- 세계의 단장증후군 시장 진단별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 신체검사
- 혈액 검사
- 변지방 검사
- 영상 검사 절차
- 기타 진단
- 세계의 단장증후군 시장 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 영양요법
- 의약품
- 수술
- 이식
- 세계의 단장증후군 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원 약국
- 전문 약국
- 기타 유통 채널
- 세계의 단장증후군 시장, (글루카곤 유사 펩티드) GLP-2하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 테두글루타이드
- 기타 GLP-2 유사체
- 세계의 단장증후군 시장 성장호르몬 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 소마트로핀
- 기타 성장호르몬 요법
- 세계의 단장증후군 시장 글루타민 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 경구 글루타민
- 정맥내 글루타민
제7장 지역별·국가별 분석
- 세계의 단장증후군 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 단장증후군 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 단장증후군 시장 : 경쟁 구도
- 단장증후군 시장 : 기업 개요
- Nestle SA Overview, Products and Services, Strategy and Financial Analysis
- Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
- Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
- Nutrinia Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Zealand Pharma
- Baxter International Inc.
- Alnylam Pharmaceuticals
- OPKO Health Inc
- Ironwood Pharmaceuticals Inc.
- Hanmi Pharm Co. Ltd
- Ardelyx Inc
- Emmaus Life Sciences Inc
- Jaguar Health
- 31.13. OxThera Inc.
- 31.14. Adocia SAS
- 31.15. EnteraBio Ltd
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 단장증후군 시장 2029 : 새로운 기회를 제공하는 국가
- 단장증후군 시장 2029 : 새로운 기회를 제공하는 부문
- 단장증후군 시장 2029 : 성장 전략
제36장 부록
ksm
Short bowel syndrome (SBS) is a malabsorption disorder that occurs due to the loss or dysfunction of a significant portion of the small intestine, leading to impaired nutrient and fluid absorption. This often results in symptoms such as diarrhea, dehydration, electrolyte imbalances, and malnutrition. The severity of these symptoms depends on the length of the remaining intestine and its ability to adapt. SBS can have a major impact on overall health, requiring careful dietary and medical management.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary types of treatments in short bowel syndrome include glucagon-like peptide (GLP-2), growth hormone, and glutamine. GLP-2, an intestinal hormone, plays a vital role in enhancing nutrient absorption, promoting intestinal growth, and reducing inflammation in the gut, making it a key focus for therapeutic approaches in conditions such as SBS. Diagnosis involves physical exams, blood tests, fecal fat tests, imaging procedures, and other assessments. Treatment options include nutritional therapy, medications, surgery, and transplants, which are provided through various channels such as hospital pharmacies, specialty pharmacies, and others.
The short bowel syndrome market research report is one of a series of new reports from The Business Research Company that provides short bowel syndrome market statistics, including short bowel syndrome industry global market size, regional shares, competitors with a short bowel syndrome market share, detailed short bowel syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the short bowel syndrome industry. This short bowel syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The short bowel syndrome market size has grown rapidly in recent years. It will grow from$2.69 billion in 2024 to $3.09 billion in 2025 at a compound annual growth rate (CAGR) of 14.9%. The growth observed in the historic period can be attributed to several factors, including the increasing prevalence of gastrointestinal disorders, rising healthcare spending and expanded insurance coverage, advancements in post-surgical management of SBS, a higher incidence of Crohn's disease and other gastrointestinal disorders, and improvements in parenteral nutrition formulations and administration techniques.
The short bowel syndrome market size is expected to see rapid growth in the next few years. It will grow to$5.33 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. The growth projected for the forecast period can be attributed to several factors, including the rising prevalence of short bowel syndrome (SBS), increasing adoption of parenteral and enteral nutrition therapies, expanding clinical research and drug development, higher healthcare expenditure, and greater awareness and early diagnosis of SBS. Key trends in the forecast period include advancements in intestinal rehabilitation therapies, the development of small intestine transplantation techniques, the adoption of telemedicine for SBS management, technological innovations in enteral feeding devices, and the integration of artificial intelligence in SBS treatment planning.
The increasing prevalence of gastrointestinal diseases is expected to drive the growth of the short bowel syndrome market in the coming years. Gastrointestinal diseases encompass a wide range of conditions affecting the digestive tract, including the stomach, intestines, liver, and pancreas, often impairing digestion and nutrient absorption. The rise in these diseases is largely driven by unhealthy dietary habits that disrupt gut health and promote inflammation. Gastrointestinal disorders can contribute to short bowel syndrome by requiring surgical removal of damaged intestinal sections, which reduces the intestine's ability to absorb nutrients. For instance, in September 2023, the Inflammatory Bowel Disease (IBD) Clinical and Research Centre reported that over 320,000 people in Canada have inflammatory bowel disease (IBD), and the prevalence is expected to increase by 2.44% annually. By 2035, an estimated 470,000 Canadians will be living with IBD. Consequently, the growing prevalence of gastrointestinal diseases is boosting the growth of the short bowel syndrome market.
Key players in the short bowel syndrome market are focusing on developing cutting-edge treatments for intestinal failure to improve outcomes for patients with gastrointestinal disorders. Intestinal failure is a serious condition where the small intestine is unable to absorb sufficient nutrients, fluids, and electrolytes, compromising hydration and nutrition. For example, in May 2024, Ironwood Pharmaceuticals, Inc., a US-based healthcare company, presented new data from studies on apraglutide, a next-generation GLP-2 analog, in adults with short bowel syndrome and intestinal failure. Apraglutide showed potential to enhance intestinal absorption and reduce dependence on parenteral support, highlighting the drug's safety, efficacy, and long-term benefits. This advancement underscores Ironwood's dedication to developing innovative therapies for gastrointestinal disorders.
In May 2024, Takeda Pharmaceutical Company Limited, a Japan-based global pharmaceutical company, partnered with Inspire, a US-based patient community platform, to address the unmet needs of short bowel syndrome patients. This collaboration aims to use real-world patient insights and multidisciplinary research to identify care gaps, improve patient support, and drive innovation in treatment approaches for short bowel syndrome. Inspire connects patients with health and wellness communities to enhance patient engagement and support data-driven solutions for healthcare challenges.
Major players in the short bowel syndrome market are Nestle SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., Alnylam Pharmaceuticals, OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co. Ltd, Ardelyx Inc, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc., OxThera Inc., Adocia SAS, EnteraBio Ltd, and GLyPharma Therapeutic Inc.
North America was the largest region in the short bowel syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in short bowel syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the short bowel syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The short bowel syndrome market consists of revenues earned by entities by providing services such as medical care, diagnostic testing, nutritional support, and ongoing patient management. The market value includes the value of related goods sold by the service provider or included within the service offering. The short bowel syndrome market also includes sales of oral rehydration solutions, antidiarrheal medications, proton pump inhibitors, antimotility agents, bile acid binders, antimicrobials, and specialized enteral nutrition formulas. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Short Bowel Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on short bowel syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for short bowel syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The short bowel syndrome market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Glucagon-Like Peptide (GLP-2); Growth Hormone; Glutamine
- 2) By Diagnosis: Physical Exam; Blood Tests; Fecal Fat Tests; Imaging Procedures; Other Diagnosis
- 3) By Treatment: Nutritional Therapy; Medications; Surgery; Transplant
- 4) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Other Distribution Channels
- Subsegments:
- 1) By Glucagon-Like Peptide (GLP-2): Teduglutide; Other GLP-2 Analogues
- 2) By Growth Hormone: Somatropin; Other Growth Hormone Therapies
- 3) By Glutamine: Oral Glutamine; Intravenous Glutamine
- Companies Mentioned: Nestle SA; Pfizer Inc; Johnson & Johnson; Sanofi SA; Nutrinia
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Short Bowel Syndrome Market Characteristics
3. Short Bowel Syndrome Market Trends And Strategies
4. Short Bowel Syndrome Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Short Bowel Syndrome Growth Analysis And Strategic Analysis Framework
- 5.1. Global Short Bowel Syndrome PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Short Bowel Syndrome Market Growth Rate Analysis
- 5.4. Global Short Bowel Syndrome Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Short Bowel Syndrome Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Short Bowel Syndrome Total Addressable Market (TAM)
6. Short Bowel Syndrome Market Segmentation
- 6.1. Global Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Glucagon-Like Peptide (GLP-2)
- Growth Hormone
- Glutamine
- 6.2. Global Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Physical Exam
- Blood Tests
- Fecal Fat Tests
- Imaging Procedures
- Other Diagnosis
- 6.3. Global Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Nutritional Therapy
- Medications
- Surgery
- Transplant
- 6.4. Global Short Bowel Syndrome Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Specialty Pharmacies
- Other Distribution Channels
- 6.5. Global Short Bowel Syndrome Market, Sub-Segmentation Of (Glucagon-Like Peptide) GLP-2, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Teduglutide
- Other GLP-2 Analogues
- 6.6. Global Short Bowel Syndrome Market, Sub-Segmentation Of Growth Hormone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Somatropin
- Other Growth Hormone Therapies
- 6.7. Global Short Bowel Syndrome Market, Sub-Segmentation Of Glutamine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral Glutamine
- Intravenous Glutamine
7. Short Bowel Syndrome Market Regional And Country Analysis
- 7.1. Global Short Bowel Syndrome Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Short Bowel Syndrome Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Short Bowel Syndrome Market
- 8.1. Asia-Pacific Short Bowel Syndrome Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Short Bowel Syndrome Market
- 9.1. China Short Bowel Syndrome Market Overview
- 9.2. China Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Short Bowel Syndrome Market
- 10.1. India Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Short Bowel Syndrome Market
- 11.1. Japan Short Bowel Syndrome Market Overview
- 11.2. Japan Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Short Bowel Syndrome Market
- 12.1. Australia Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Short Bowel Syndrome Market
- 13.1. Indonesia Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Short Bowel Syndrome Market
- 14.1. South Korea Short Bowel Syndrome Market Overview
- 14.2. South Korea Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Short Bowel Syndrome Market
- 15.1. Western Europe Short Bowel Syndrome Market Overview
- 15.2. Western Europe Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Short Bowel Syndrome Market
- 16.1. UK Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Short Bowel Syndrome Market
- 17.1. Germany Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Short Bowel Syndrome Market
- 18.1. France Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Short Bowel Syndrome Market
- 19.1. Italy Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Short Bowel Syndrome Market
- 20.1. Spain Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Short Bowel Syndrome Market
- 21.1. Eastern Europe Short Bowel Syndrome Market Overview
- 21.2. Eastern Europe Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Short Bowel Syndrome Market
- 22.1. Russia Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Short Bowel Syndrome Market
- 23.1. North America Short Bowel Syndrome Market Overview
- 23.2. North America Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Short Bowel Syndrome Market
- 24.1. USA Short Bowel Syndrome Market Overview
- 24.2. USA Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Short Bowel Syndrome Market
- 25.1. Canada Short Bowel Syndrome Market Overview
- 25.2. Canada Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Short Bowel Syndrome Market
- 26.1. South America Short Bowel Syndrome Market Overview
- 26.2. South America Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Short Bowel Syndrome Market
- 27.1. Brazil Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Short Bowel Syndrome Market
- 28.1. Middle East Short Bowel Syndrome Market Overview
- 28.2. Middle East Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Short Bowel Syndrome Market
- 29.1. Africa Short Bowel Syndrome Market Overview
- 29.2. Africa Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Short Bowel Syndrome Market Competitive Landscape And Company Profiles
- 30.1. Short Bowel Syndrome Market Competitive Landscape
- 30.2. Short Bowel Syndrome Market Company Profiles
- 30.2.1. Nestle SA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Nutrinia Overview, Products and Services, Strategy and Financial Analysis
31. Short Bowel Syndrome Market Other Major And Innovative Companies
- 31.1. GlaxoSmithKline plc
- 31.2. Takeda Pharmaceutical Company Limited
- 31.3. Zealand Pharma
- 31.4. Baxter International Inc.
- 31.5. Alnylam Pharmaceuticals
- 31.6. OPKO Health Inc
- 31.7. Ironwood Pharmaceuticals Inc.
- 31.8. Hanmi Pharm Co. Ltd
- 31.9. Ardelyx Inc
- 31.10. Emmaus Life Sciences Inc
- 31.11. Jaguar Health
- 31.12. 9 Meters Biopharma Inc.
- 31.13. OxThera Inc.
- 31.14. Adocia SAS
- 31.15. EnteraBio Ltd
32. Global Short Bowel Syndrome Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Short Bowel Syndrome Market
34. Recent Developments In The Short Bowel Syndrome Market
35. Short Bowel Syndrome Market High Potential Countries, Segments and Strategies
- 35.1 Short Bowel Syndrome Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Short Bowel Syndrome Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Short Bowel Syndrome Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
- 250617_r34967_Short_Bowel_Syndrome_GMR_2025
